Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01254864 · ClinicalTrials.gov registry record · Phase 2
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 190
- Enrollment target
NCT01254864: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01254864 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 190 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01254864, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 190 participants
- Enrollment target
Study Summary
You are being asked to take part in this study because you have prostate cancer that has spread to other parts of the body. This is an investigational study. Prednisone is FDA-approved and commercially available. Abiraterone acetate is FDA-approved and commercially available, but is still being researched. Sunitinib malate is FDA-approved for the treatment of gastrointestinal tumors and renal cell carcinoma, and dasatinib is FDA approved and commercially available for certain types of leukemia. The use of these drugs in prostate cancer and in combination with abiraterone acetate and prednisone is investigational. Up to 180 patients will be enrolled in this study. All will be enrolled at MD Anderson.
Interventions
- DRUG Sunitinib
- DRUG Prednisone
- DRUG Dasatinib
- DRUG Abiraterone Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2011-03-16 |
| Est. Completion | 2023-12-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01254864
The ClinicalTrials.gov registry entry for NCT01254864 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Sunitinib is the first listed.
NCT01254864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01254864 about?
NCT01254864 is a clinical study titled "Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies". You are being asked to take part in this study because you have prostate cancer that has spread to other parts of the body. This is an investigational study. Prednisone is FDA-approved and commercially available. Abiraterone acetate is FDA-approved and commercially available, but is still being res...
What is the current status of trial NCT01254864?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 2011-03-16. Estimated completion is 2023-12-07.
What interventions are being tested in trial NCT01254864?
The interventions under investigation include: Sunitinib (DRUG), Prednisone (DRUG), Dasatinib (DRUG), Abiraterone Acetate (DRUG).
Who is sponsoring clinical trial NCT01254864?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.